Funding to Accelerate New Discovery and Development and Increase Drilling Capacity to More Than 100,000 Meters Annually

SYDNEY and LOS ANGELES, Jan. 27, 2025 — Earth AI, a predictive explorer for clean energy metals using artificial intelligence (AI), has announced $20M in Series B funding. The oversubscribed round was led by Tamarack Global and Cantos Ventures. Participating investors include Overmatch, Alpaca, Sparkwave Capital, and significant support from existing investors including Y Combinator and Scrum Ventures. New funding will drive AI and drilling technology development and accelerate project value discovery. The company plans to increase the project pipeline to over 50 sites and increase drilling capacity to 100,000 meters at an industry beating ~$100/meter cost.

Founded in 2017, Earth AI is disrupting the mining industry through its AI-powered Mineral Targeting Platform (MTP) that is capable of rapidly identifying mineral resources in previously untapped areas at a fraction of the cost. Combined with proprietary mobile low disturbance, drilling technology (MLD), the company’s approach has achieved an industry-leading discovery success rate of 75% (compared to an estimated industry average of 0.5%¹), while reducing exploration costs by up to 80%.

“Despite the tremendous global need for mineral resources for everything from the energy transition to day-to-day life, new mineral deposit discoveries are notorious for being expensive and time consuming,” said Roman Teslyuk, founder and CEO of Earth AI. “Earth AI is changing this paradigm using its proprietary AI and drilling technology that has already made verified discoveries in greenfield regions. This new round of funding will be critical to expanding our operations and establishing a pipeline of attractive new mining projects for the industry.”

Earth AI’s model is focused on identifying mineral deposits using AI, validating them through drilling and then selling the multi-billion-dollar mining rights to large cap mining companies. The company’s predictive technology has been extensively trained using continental scale data sets that combine and contextualize 400 million pieces of disparate information along with satellite remote sensing to identify greenfield prospects–a key differentiator to other exploration technologies that focus on identifying resources near existing mines. This ability makes Earth AI an integral partner for the mining industry as it seeks to meet the exponential growth in demand for critical minerals resulting from the global energy transition.

“We are always attracted to companies operating in large addressable markets like critical minerals that have found unique ways to create superior cost structures and defensibility in their approach. Earth AI fits squarely within this target and has already proven industry leading success rates using their AI engine, the Mineral Targeting Platform, which we believe to be the best trained model amongst any other players in the space.  We are very excited to lead this round and believe the future is very bright for this incredible company,” said Jamie Lee, managing partner at Tamarack Global 

Global demand for critical minerals is expected to reach $10tn by 2050 and current production will need to increase ~30x to meet that threshold. Many mining companies are focused on extraction, while discovery and exploration is outsourced to a fragmented market of micro-cap companies whose efficiency has declined by ~70% over the last decade. Leveraging the latest technology, Earth AI is poised to become the origination engine of the mining industry, providing organic growth of new mining assets to an industry that desperately needs it to meet the coming tidal wave of demand.

To date, Earth AI has announced the following discoveries during the fourth quarter of 2024:

About Earth AI
Earth AI, founded in 2017, is a predictive explorer and driller for clean energy metals that is disrupting the mineral industry through a novel approach using AI-powered mineral deposit discovery software and proprietary low disturbance drilling technology. The company’s technology has achieved an industry-best 75% discovery success rate, while at the same time speeding up the mineral exploration process by 4x and reducing costs by up to 80%. The company operates in Sydney, Australia, and  Los Angeles, CA.

Earth AI Contact:
Monte Hackett
CFO
[email protected]

Earth AI Media Contact:
Chris Allieri
[email protected]

SOURCE Earth AI

LOS ANGELES, Jan. 27, 2025 — Meaningful Partners LLC (“Meaningful Partners”), a private equity firm based in Los Angeles, California exclusively focused on the consumer sector, is proud to announce the final closing of its 2nd fund, Meaningful Partners Dedicated Capital Vehicle ii LP with over $150mm of capital commitments. With this recent closing Meaningful Partners now has approximately $500mm of Assets under Management.

Meaningful Partners secured commitments from both existing and new investors comprising a diversified investor group including leading endowments, foundations, consultants, fund of funds and family offices. 

“We are excited to have closed our second fund and are proud to partner with an extremely high quality group of investors. This support is testament to the confidence our investors have in our investment approach and growing team,” commented Jake Capps, Co-Founder & Managing Partner of Meaningful Partners.

“This closing allows us to continue to execute on our strategy and deepen firm operating capabilities for the benefit of accelerating growth and performance at partner companies. With an exceptional team and our Expert Community we are well positioned to partner with beloved consumer companies through control and significant minority transactions in the food & beverage, multi-unit services, VMS/Beauty and home and commercial services sectors,” added Co-Founder & Managing Partner, Amin Maredia.

About Meaningful Partners

Meaningful Partners, with offices in Los Angeles, CA, and Austin, TX, invests in consumer businesses that have earned customer trust, foster loyalty, demonstrate a commitment to all stakeholders, and are led by management teams driving positive purpose and performance.  We make control and minority equity investments ranging from $15 million to $100+ million in lower-middle-market and growth companies poised for rapid scaling. Our experienced team of investors and operators is complemented by an Expert Community of 45+ CEOs, founders, and category specialists, with over 850 years of domain expertise. Together, we work to accelerate growth and create meaningful impact from day one.  For more information, visit www.meaningfulpartners.com

Buchalter served as legal counsel to the fund

SOURCE Meaningful Partners

The new fund will partner with visionary entrepreneurs, support transformative technologies, and make automation accessible for the industries that need it most.

JACKSONVILLE, Fla., Jan. 27, 2025 — 2,750 miles away from Silicon Valley, Matthew Chang, founder of Chang Robotics, announces his next business venture: The Chang Robotics Fund. The Fund aims to address the numerous needs and market opportunities the Chang Robotics engineering team identified in their daily operations by investing in disruptive technologies designed to confront the industry’s most urgent challenges—from labor shortages to energy efficiency to environmental remediation. By utilizing innovative intellectual property and the engineering and management expertise of Chang Robotics, the Fund seeks to scale its targeted innovations into impactful, transformative, and profitable businesses.

Global industries, from manufacturing to healthcare, face mounting pressures such as intensifying global competition, workforce constraints, escalating expenses, and the urgent need for environmental restoration. Tackling these issues demands a new paradigm of intelligent automation, energy efficiency, and sustainable innovation.

The Fund’s investments target early-stage innovators in smart manufacturing, robotics, industrial AI, and energy transformation, developing localized solutions with global applications.

We don’t just fund innovation—we build the industry leaders of tomorrow.

The idea for the Fund was inspired by Matthew Chang’s track record of collaborating with talented startups and investing in them using Chang Robotics engineering expertise. “Our company has a strong ability to spot ideas with real potential,” said Chang. “Through The Chang Robotics Fund, we’re investing in startups that will shape the future of their industries. I’m confident the companies we support will achieve great success in the years ahead.”

The Fund team is a conglomerate of experts from various fields, bringing an unparalleled diversity of wisdom to this project. Matthew Chang, the General Partner, is joined by Dr. Don Capener, Fund Strategist, Forrest Hayes Jr., Fund Director, Robert Sterling, Chief Financial Officer, and Phil Hudgens, Fund Controller. Their fields of experience include asset management, serial entrepreneurship, engineering, venture capital, academia, corporate M&A, and investment banking, amongst others. Their ventures have reached across global markets—spanning the US, Europe, Africa, the Middle East, and Asia-Pacific—demonstrating a deep understanding of diverse markets and economies.

The key to the success of this fund lies in the unique relationship that Chang Robotics has with each potential portfolio company. Whether it is engineering, robotics automation, or consulting, Chang Robotics will work with each portfolio company to ensure their innovations come to life. When asked about this concept, Forrest Hayes, Fund Director, said, “Those relationships with our investment companies, along with the insider knowledge we gain, are critical. Matthew has the vision to harness the intellectual property and capital to conceive a product that fits into the market and will lead to substantial returns for our stakeholders.”

On January 29^th at 2:00 pm EST. Matthew Chang will join Robert Sterling, CFO and friend of the Fund, to share more of the story behind the Chang Robotics Fund and dive into the trends reshaping automation and investment. If you are interested in investing or simply hearing more about the Fund’s vision, you can register here.

For more information, visit CR.Fund or contact [email protected] and follow us on LinkedIn for weekly updates.

About Chang Robotics
Chang Robotics is a DBE-certified engineering firm at the forefront of advanced manufacturing, collaborative robotics, and disruptive automation. Founded in 2017, Chang Robotics has rapidly grown, delivering innovative, data-driven solutions, including some of the world’s largest autonomous systems. Recognized as one of Fast Company’s 2024 Best Workplaces for Innovators, the company revolutionizes supply chain automation and enhances workforce productivity through human-focused robotics. With a commitment to sustainability and cutting-edge technology, Chang Robotics empowers businesses across manufacturing, government, healthcare, and beyond. More information is available at ChangRobotics.ai and on LinkedIn.

SOURCE Chang Robotics

Led by Ocean Azul Partners and marketing & advertising industry executives to redefine how AI agents and human marketers collaborate

NEW YORK, Jan. 27, 2025 — MarkeTeam.ai, (“MarkeTeam”) developer of advanced artificial intelligence technology for the marketing industry, today announced the completion of a $3 million seed funding round. Having recently launched its next-generation autonomous marketing agents, the company already operates a team of virtual experts across core marketing disciplines, including brand marketing, strategic planning, paid media, social media management, content marketing, and SEO.

MarkeTeam’s AI agents are trained for multi-human / multi-agent collaboration and on real marketing operations & campaign data, enabling them to integrate seamlessly into organizational platforms and collaborate naturally with human teams. Unlike traditional AI tools that assist with isolated tasks as “co-pilots”, each of MarkeTeam’s agents functions as full-fledged team member, capable of undertaking comprehensive marketing “work units” spanning research & ideation, planning, creation, publishing & optimization in a collaborative manner. This AI-native approach allows organizations to redirect budgets from operational costs to growth initiatives & working media, improving overall performance and ROI.

Ocean Azul Partners led the funding round with participation from marketing and advertising industry veterans including Clive Sirkin (former CMO of Kellogg’s and Kimberly-Clark), Dion Joannou (former CEO of Accedian), Mitch Mayers (Founder and Partner at Zipatoni, later acquired by IPG), Tony Weisman (former CMO of Dunkin’ Brands) and additional industry leaders. To date, the company has raised $5 million.

“MarkeTeam represents a fundamental shift in how we imagine the future of work,” said Alex Tellez, Managing Director at Ocean Azul Partners. “MarkeTeam leverages decades of marketing experience to train, validate, and deploy one of the most innovative solutions we’ve seen in this space. MarkeTeam is creating a new paradigm where AI agents and human talent collaborate smoothly, driving efficiency and innovation across the entire business function.”

As companies increase their marketing KPIs and goals, budgets are under pressure. A recent Gartner survey reveals that the average marketing budgets have fallen by 15% over the past year, forcing CMOs and marketing leaders to ‘do more with less’.

“Marketing teams are under constant pressure to deliver exceptional results despite shrinking budgets and resources,” said Naama Manova-Twito, Co-Founder & CEO. “At MarkeTeam, we’re challenging the status quo by introducing AI agents that are not ‘tools’ but true ‘team members’. We are building the technology that will enable you to move from using Generative AI on a “fractional task” basis to having the ability to export entire “work units” to virtual employees. With the support of Ocean Azul, our visionary investors, and our incredible team, we’re redefining the future of marketing and the workplace itself.”

These AI team members operate autonomously across the entire marketing spectrum. They learn brand voice and strategy, track market dynamics, conduct independent research, proactively plan, execute in real-time, and continuously optimize performance. This collaboration transforms teams’ operations, delivering measurable results while significantly cutting costs.

The funding will accelerate MarkeTeam’s expansion in the U.S. market while driving the development of new AI models, marketing agents and capabilities across multiple channels.

“Unlike most LLMs trained with standard instructional tuning, our models are designed for collaboration and optimized for marketing-specific metrics,” said Sahar Millis, Co-Founder & CTO of MarkeTeam. “This enables us to build Agents as Virtual Workers, already designed for the next evolutionary step in the workspace – hybrid teams.”

About MarkeTeam.ai

MarkeTeam.ai is transforming the marketing industry with its proprietary autonomous AI agents and models for marketing. MarkeTeam.ai empowers businesses to exceed their KPIs without increasing budgets or headcount. The company’s AI-native approach allows organizations to allocate more of their budget towards substantial growth initiatives rather than operational overhead, effectively addressing the common challenge of achieving growing objectives with limited resources.

For more information, visit: MarkeTeam.ai

Contact: Sivan Ron, [email protected] 

SOURCE MarkeTeam.ai

Semi-Autonomous Venture Capital Fund Identifies and Supports Innovation in AI Tools that Execute Complex Business Tasks, a Multi-Trillion Dollar Opportunity in 2025

SEATTLE, Jan. 27, 2025 — Agent Fund, a semi-autonomous venture capital fund investing in AI autonomous agent startups, launched today on AngelList led by Yohei Nakajima (GP at Untapped Capital and creator of BabyAGI), Adam Silverman, and Alex Reibman (co-founders of Agen.cy AI and creators of AgentOps.ai,). Agent Fund focuses on identifying and supporting innovative startups within the burgeoning autonomous agent ecosystem, and will operate semi-autonomously itself by leveraging AI for deal sourcing, due diligence, portfolio management and community-building.

Autonomous agents represent the next evolution of AI tools, transcending simple prompts and API calls to dynamically decide what to do based on objectives, and utilizing tools, memory, and reasoning to execute complex tasks. 

Nakajima created Baby AGI in April 2022, a fully autonomous task manager that can create, track, prioritize and execute a company’s projects using artificial intelligence. Since then, hundreds of founders have reached out to him for funding, inspiring a separate investment strategy. He teamed up with Silvernam and Reibman who help businesses build AI agents and were also seeking an investment strategy.

“Agent Fund is the perfect playground for startups who are pushing the boundaries of what we can automate with AI,” said Nakajima. “Our goal is to build a large, collaborative community of autonomous agent startups and for the Fund to be semi-autonomous itself. We will still have people making key decisions, but leverage AI across all aspects of the business from sourcing deals to selecting the people to invest in and managing the portfolio.”

AI agents are a multi-trillion dollar opportunity¹ and Agent Fund is well positioned to fuel innovation in this space with its extensive network, bolstered by the global recognition of BabyAGI. Agent Fund supports startups at scale, covering diverse use cases from infrastructure to AI employees, enterprise tools, and no-code solutions, making it a preferred partner for top-tier startups.

Agent Fund is structured as a rolling fund on AngelList, with individual investments ranging from $50,000 – $200,000 each. For additional information or to become an investor, visit https://venture.angellist.com/v/back/agent-fund.

About the Agent Fund Team
Yohei Nakajima is a GP at Untapped Capital, which will serve as operator of the fund. He has experience investing in autonomous agent startups, including Cognosys, E2B, Azara, Open Souls, and Wokelo. Agen.cy AI co-founders Alex Reibman (CEO) and Adam Silverman (COO) built AI agents for data entry automation and developed one of the top ChatGPT plugins before starting Agen.cy. Alex has led machine learning engineering teams at Ernst & Young and developed ML solutions for Goldman Sachs, American Express, and Westpac. Adam is known in the “agent” world for his weekly recap threads and running one of the largest communities of agent developers.

PR Contact:
Karen Blondell for Untapped Capital
424-263-7371
[email protected]

¹ https://yhoo.it/3EbuuMk 

SOURCE Untapped Capital

HUNTINGTON, N.Y., Jan. 27, 2025 — A newly published paper in the Global Journal of Addiction & Rehabilitation Medicine further expands on the U.S. Surgeon General’s advisory, linking frequent alcohol consumption and hangovers to chronic systemic inflammation and heightened cancer risk. Fortunately, Sen-Jam Pharmaceutical’s innovative therapeutic, SJP-001, is specifically designed to target this inflammatory pathway, offering a groundbreaking solution to mitigate alcohol-induced health risks.

“The Surgeon General’s advisory highlights inflammation as a mechanism linking alcohol consumption to cancer formation, a connection aligned with our research,” said Jacqueline Iversen, RPh, MS, Founder and CCO of Sen-Jam Pharmaceutical. “Our therapeutic under development, SJP-001, is designed to intervene in this inflammatory process, reducing both immediate effects like hangovers and long-term health risks. This would be a significant step forward in reducing disease burden to the millions of people who enjoy consuming alcohol.“

The paper, published on the heels of the Surgeon General’s advisory, underscores that frequent hangovers can lead to chronic systemic inflammation, a major risk factor for developing cancers and other diseases. SJP-001 directly targets this inflammatory cascade, providing dual-action benefits: immediate relief from hangover symptoms and potential long-term reduction of systemic chronic inflammation.

“Sen-Jam’s research represents a major advancement in understanding and potentially mitigating alcohol-related risks,” said Joris Verster, PhD, Sen-Jam Scientific Advisor and lead author of the newly published paper. “Our findings support the development of innovative therapies like SJP-001, which not only address the immediate symptoms of alcohol hangover but also target the root causes of chronic inflammation.”

Early clinical data from testing SJP-001, a novel combination of two pharmaceutical agents, revealed significant reductions in hangover severity. A larger double-blind, placebo-controlled trial is currently underway with Novotech, a global full-service clinical Contract Research Organization (CRO). Beyond immediate symptom relief, the therapeutic potential to address chronic inflammation positions it as a breakthrough in mitigating long-term health risks associated with alcohol consumption.

The market potential for SJP-001 is substantial. The global hangover remedy market was valued at $2.34 billion in 2023 and is projected to grow to over $6 billion by 2030 at a compound annual growth rate (CAGR) of 14.9%. According to Destum Partners’ – Market Analysis & Valuation, SJP-001’s current projected valuation of $107 million in the U.S. and Europe is anticipated to surge to $688 million by 2027, fueled by the successful completion of clinical trials and securing commercial approval. These projections underscore the economic and societal value of bringing the first FDA-approved, scientifically validated hangover remedy to market.

“Our mission is to develop safe, effective solutions for the millions impacted by alcohol-induced inflammation,” said Jim Iversen, CEO of Sen-Jam Pharmaceutical. “The Surgeon General’s advisory reinforces the importance of innovations like SJP-001 to address both immediate and long-term health risks.”

To learn more about Sen-Jam Pharmaceutical and SJP-001, visit www.sen-jam.com.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical is a pioneering biotech company transforming the treatment landscape for inflammation and metabolic disorders. Through its proprietary “Pleiotropic Anti-Inflammatory Remedies” (PAIR) technology, Sen-Jam delivers precision therapies that work in harmony with the body’s immune system to mitigate systemic risks associated with chronic inflammation while supporting long-term health and vitality. To learn more visit wefunder.com/senjam. 

CONTACT INFORMATION:
Sen-Jam Pharmaceutical
Christine Leonard
[email protected]
781-913-1902

SOURCE Sen-Jam Pharmaceutical

New Women’s Heart Health-Focused Service Aims to Solve Physician Access Crisis with Innovative Group Virtual Care Solution

BOSTON, Jan. 27, 2025 — Systole Health, a tech-enabled group virtual care solution for women’s heart health, today announced $2M in pre-seed funding. The round was led by Benchstrength, with participation from January Ventures, J Ventures, and Tom X. Lee, founder of One Medical.

Systole Health delivers comprehensive care for women’s heart health through innovative group virtual visits. Women at risk for heart disease meet with a doctor and health coach to receive personalized coaching, medical care, and a supportive community in hour-long appointments. This program is a proven, yet underused, group care model that offers women the opportunity to ask questions and get expert care and support. By comparison, the current average doctor-patient visit is 18 minutes, primarily focused on medication management, an issue compounded by physician shortages and accessibility challenges as patient volumes continue to increase. Systole Health is available directly to consumers and will become available through partnering health systems as the program expands.

Heart disease is the leading cause of death among women, with 90% of women having at least one heart disease risk factor and 45% already carrying diagnoses of cardiovascular disease (CVD). Despite these alarming statistics, women are underdiagnosed and undertreated for heart disease risk factors.

“When we look at investments, we prioritize new companies that address an unmet need with a novel approach, brought to us by founders who have both vision and a distinct ability to execute,” said Ken Chenault Jr., Managing Partner at Benchstrength. “Systole Health meets all these criteria with its innovative group virtual care model, which leverages technology to provide scalable and sustainable solutions for women’s heart health. Their patient-first approach, designed specifically to address systemic gaps in cardiovascular care for women, is transformative, and we’re excited to support their mission to deliver meaningful outcomes and expand access to quality care.”

Dr. Simin Lee, CEO and founder of Systole Health notes, “Our mission is to bend the curve of heart disease in women by introducing a new care model that prioritizes outcomes and connection. As a cardiologist, I have witnessed firsthand the struggles women face in managing their heart health. Our solution is built for women by women, addressing the unique challenges we experience and expanding access to the kind of care we want for our mothers, aunts, sisters, and daughters.”

Lauren McConnell, COO and founder of Systole Health adds, “We know there’s a lot of women looking for help with their heart health, without the option to get into their existing providers as much as they need to. I’m excited to build a supportive, community-driven space for those women, extending their lives and by extension – improving the health of their families.”

Systole Health plans to utilize the funding to expand into key markets throughout the United States and build its early clinical team. The company is also focused on forming strategic partnerships with healthcare providers and payers to further integrate its services into the broader healthcare ecosystem. Currently, the program is being piloted and serving patients in Massachusetts and Florida.

“At Systole Health, we’ve seen how this model can do more with less and unlock the power of community for our patients,” says Dr. Lee. “This is exactly the kind of solution needed to truly move the needle for women’s heart health.”

About Systole Health

Based in Boston, Systole Health is a pre-seed start-up revolutionizing women’s heart health through its innovative, tech-enabled group virtual care model. Focused on addressing systemic gaps in cardiovascular care, Systole Health delivers scalable, community-driven solutions that prioritize access, outcomes, and patient connection. Led by Dr. Simin Gharib Lee, a Harvard-trained cardiologist, and Lauren McConnell, a digital health innovator, the company is backed by Benchstrength, January Ventures, J Ventures, and Tom X. Lee. For more information, visit www.systolehealth.com.

Media Contact: 

Vikki Herrera
Oak Street Communications for Systole Health
[email protected]

SOURCE Systole Health

PHOENIX, Jan. 27, 2025 — Trinity Capital Inc. (NASDAQ: TRIN) (“Trinity Capital”), a leading alternative asset manager, today announced the commitment of $30 million in growth capital to Elucent Medical (“Elucent”), a pioneering medical technology company transforming the field of guided surgical technologies.

Elucent amplifies the field of surgical guidance, transforming standard instruments into smart tools with In-Body Spatial Intelligence™, giving physicians true 3D surgical awareness for unmatched precision.  Based in Eden Prairie, Minnesota, Elucent developed the EnVisio^® System, which uses a spatial field generator measuring continuous data points across multiple planes, to display exact 3D positioning of the SmartClip^® marker and SmartSensor™ used to guide soft-tissue surgical excision. EnVisio’s adaptive design and seamless integration redefine surgical precision, enabling an intuitive, uninterrupted experience that enhances precision and accuracy for better outcomes.   

“Elucent is disrupting the field of surgical guidance with its cutting-edge technology,” said Lauren Cosentino, Managing Director, Life Sciences at Trinity Capital. “We are thrilled to be a part of Elucent’s journey as they continue to innovate and improve surgical outcomes.”

“Our EnVisio® System gives surgeons confidence before, during, and after their surgical procedures so they know they have delivered unparalleled accuracy and precision for their patients. We are in scale mode and are excited to partner with Trinity Capital,” said Jason Pesterfield, CEO at Elucent. Trinity Capital’s investment will be key to our continued acceleration of our innovation and commercialization efforts.”

Earlier in 2024, Elucent raised $44.0 million in its Series C funding round. This additional growth capital will be used to scale operations.

About Trinity Capital Inc.

Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager, aiming to provide investors with stable and consistent returns through access to the private credit market. We source, vet, and invest in dynamic privately funded growth-oriented companies, giving our investors access to a strong and diversified portfolio. With distinct business verticals, Trinity Capital stands as a trusted partner for innovative companies seeking tailored growth capital solutions. Headquartered in Phoenix, Arizona, the firm has an international footprint, supported by a dedicated team of strategically located investment professionals. For more information, visit the company’s website at trinitycapital.com and stay connected by following us on LinkedIn and X (formerly Twitter).

About Elucent Medical:

Elucent Medical is a leading innovator in the field of guided surgical technologies, dedicated to improving patient outcomes through precision and accuracy. The company’s flagship technologies, EnVisio^® and SmartClip^®, offer groundbreaking solutions for soft-tissue surgical guidance with In-Body Spatial Intelligence™ (iSi). With a commitment to innovation and collaboration, Elucent Medical is driving advancements in surgical oncologic care, making a positive impact on the lives of patients and the medical professionals who treat them.

For more information about Elucent Medical and its innovative solutions, please visit www.elucent.com.

SOURCE Trinity Capital Inc.

SHANGHAI, Jan. 27, 2025 — On January 27th, 2025, Beijing Time, Qiming Venture Partners’ portfolio company HyperStrong, a leading provider of battery energy storage systems (BESS) in China, successfully debuted on the Shanghai Stock Exchange’s Science and Technology Innovation Board (the “STAR Market”).

HyperStrong (SHSE:688411) was issued at RMB 19.38 per share and closed at RMB 63.80, representing an increase of 229.21% from the issue price, with a market capitalization of RMB 11.339 billion.

Qiming Venture Partners has been an early investor in HyperStrong since 2015 and has continued to support the company’s growth through subsequent funding rounds. HyperStrong’s successful IPO marks Qiming’s first IPO milestone of 2025.

Founded in 2011, HyperStrong has established itself as a trusted partner in the global transition to renewable energy. The company provides a wide range of energy storage solutions including liquid-cooling energy storage systems, outdoor cabinets, all-in-one charging and storage systems for utility-scale, commercial and industrial uses.

With the increasing global demand for renewable energy, utility-scale energy storage systems have become essential for ensuring grid stability and safety. HyperStrong has positioned itself as a top-tier BESS provider, leveraging its strengths in battery digital modeling, energy and thermal management, big data platform, system integration, and rigorous testing capabilities. These technologies enable HyperStrong to meet the diverse and evolving needs of its customers.

According to S&P Global Commodity Insights, HyperStrong ranked among the top three BESS integrators in terms of global capacity installed in 2023.

Dr. Jianhui Zhang, Chairman and CEO of HyperStrong, expressed his vision for the company: “HyperStrong remains committed to unlocking the full lifecycle value of energy storage systems. We aim to deepen our presence across the energy storage value chain, enhance our integration capabilities, and foster a collaborative innovation ecosystem. By advancing digital applications, hardware-software synergies, and comprehensive solutions, we will drive rapid product innovation to meet the ever-changing needs of the global market.”

Alex Zhou, Managing Partner of Qiming Venture Partners, said, “Over the past decade, we have supported HyperStrong as an investor, shareholder, and board member, steadfastly accompanying the company throughout its remarkable growth. We have witnessed HyperStrong leverage its cutting-edge R&D, strategic market insights, and relentless spirit of innovation to become a leader in the competitive energy storage industry. Today’s successful IPO is not only a major milestone in its journey but also the start of an exciting new chapter full of potential. As the global energy sector undergoes a transformative shift, energy storage has become a critical pillar of this change. We expect HyperStrong to continue leading the way in technological innovation, solidifying its position as a key player in the global energy storage market.”

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, UBTech, WeRide, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, New Horizon Health, Sanyou Medical, AmoyDx, Berry Genomics, SinocellTech, Yuanxin Technology, Caidya, Belief BioMed, among many others.

SOURCE Qiming Venture Partners